Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech Startup Investors in Germany

Last updated: Jul 2024 A list of 50 angel investors and VC funds that invest in Biotech startups based in Germany. We rank investors based on the number of investments they made in Biotech companies from Germany. We update this investor list every month.

Top 50 Biotech Startup Investors in Germany

Investor	Biotech Germany investments
HTGF \| High-Tech Gruenderfonds	36
Boehringer Ingelheim Venture Fund	16
NRW.BANK	15
KfW	15
MIG Capital	15
Bayern Kapital	11
Wellington Partners	8
TGFS - Technologiegründerfonds Sachsen	8
IFB Innovationsstarter	7
eCAPITAL ENTREPRENEURIAL PARTNERS	6
coparion	6
BioMedPartners	6
BayBG Venture Capital	5
bmp Ventures	5
bm-t beteiligungsmanagement thuringen	5
EMBL Ventures	5
Forbion Capital Partners	5
Techno Venture Management	5
Creathor Ventures	5
BlueYard Capital	4
EIC Fund	4
Seed Fonds Aachen	4
IBB Ventures	4
TVM Capital	4
S-Venture Capital Dortmund	4
Amino Collective	4
EQT Life Sciences	4
EQT Ventures	4
Brandenburg Kapital	4
SFO	3
Gilde Healthcare	3
Global Asset Fund	3
Think.Health	3
b.value AG	3
Seventure Partners	3
Counteract	3
Andrew Keys	3
UVC Partners	3
Taavet Hinrikus	3
Grazia Equity	3
LSP BioVentures	3
DvH Ventures	3
OCCIDENT	3
Cascara Ventures	3
Possible Ventures	3
Delivery Hero Ventures	3
CPT Capital	3
German Federal Ministry of Education and Research (BMBF)	3
Lima Ventures	3
Andera Partners	3

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

StoryBox — StoryBox provides a Software as a Service solution for businesses to create, share and structure video content to make it searchable. With the system, companies can create and organize smartphone-based videos for any application scenario. Using the app, videos can be created and shared by every employee using templates. The app suggests picturesettings and scene lengths automatically and offers an automated creation which includes corporate design. The content can be stored in the DSGVO-compliant StoryBox cloud and can be accessed, filtered and analyzed from anywhere. Customers include Iveco, Erste Group, Evonik, Alten, and KTM.
Heidelberg Epignostix — Heidelberg Epignostix is a pioneering start-up led by a dedicated team of DNA methylation-based tumor categorization experts. Heidelberg Epignostix has revolutionized tumor categorization by using the strength of methylation-based algorithms.
InSpacePropulsion Technologies — ISPTech is a Spin-Off of the Institute of Space Propulsion at the German Aerospace Center (DLR). It offers non-toxic, green propulsion solutions

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

Investment focus

Biotechnology, Software, Information Technology
Seed, Series A, Series B
Germany, United States, United Kingdom

Portfolio highlights

widu — widu enables real estate and accommodation companies to source visuals (photography, video, drone) at scale through its serviced marketplace
Black Semiconductor — Black Semiconductor manufacture microchips with integrated electronic-photonic circuits using graphene technology.
Prothea Technologies — Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit.

KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the LÃ¤nder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Series B
Germany, India, Kenya

Portfolio highlights

Uniper — Uniper is an international energy company with about 11,000 employees. They combine a balanced portfolio of technologically advanced large-scale assets with outstanding technical and commercial expertise. Uniper is a German energy company based in Dusseldorf, North Rhine-Westphalia. It was formed by the separation of E.ON's fossil fuel assetsinto a separate company that began operating on 1 January 2016.
Vectoflow — Vectoflow is an innovative company developing fluid-dynamic metrology devices for fluid flow and dynamics measurement. It offers standardized and customized flow measurement technology that measures the static and total pressure, velocity, and angle of attack of a flow. These products are used in motorsport, aviation, turbine machine development,and research sectors.
Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.

Zusammen gestalten wir die Unternehmen von morgen.

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
Germany, France, Austria

Portfolio highlights

HawkCell — A plug-and-play solution turning human MRI into the first animal-dedicated imaging enhanced with AI algorithms. A unique MRI solution.
Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
Innatera — Innatera is a Dutch nanotech company and an offspring of the Delft University of Technology in the Netherlands.

Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.

Investment focus

Software, Health Care, Information Technology
Seed, Series A, Funding Round
Germany, United States, Finland

Portfolio highlights

planqc — planqc quantum computers store information in individual atoms – nature's best qubits. Quantum information is processed by arranging these qubits in highly scalable arrays and manipulating them with precisely controlled laser pulses. planqc unique combination of quantum technologies is the fastest way to scale to thousands of qubits, aprerequisite for industry-relevant quantum advantage.
Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
Proxima Fusion — We are a European fusion energy startup pursuing the clearest path to grid deployment.

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Germany, United States, United Kingdom

Portfolio highlights

Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.
Onward — Working to restore movement, independence, and health in people with spinal cord injury.
Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.

TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.

Investment focus

Software, Information Technology, Manufacturing
Seed, Funding Round, Series A
Germany, United States

Portfolio highlights

MiViA — From microstructure segmentation to grain size measurement! Our AI engine provides a fast and reliable metallographic analysis for metallic products.}
Packwise — Packwise is bringing Intermediate Bulk Containers (IBCs) to the Internet of Things. Their Packwise Smart Cap makes a container intelligent and allows for improved and automated packaging management and logistics. Millions of IBCs are being used by chemical, pharmaceutical and food companies every day. Their Packwise Smart Cap is narrow-band LPWANconnected and provides users with real-time information on the state and location of containers.Packwise develops ready-to-use web applications and can be integrated with existing in-house IT or software through web service API.Packwise GmbH is a German company based in the Silicon Saxony. Packwise is Europe’s pioneer in digital industrial packaging management (IBCs and drums).
watttron — Watttron invents a revolutionary heating system that can heat up surfaces heterogeneously.Watttron develops an innovative heating technology that can be used in various industrial processes. It is superior to current heating systems in many ways and offers a number of advantages. On the following pages, you will find information about possibleapplications and opportunities.The company is located in the Technologie- und Gründerzentrum Freital – a technology and start-up center on the outskirts of Dresden, the state capital of Saxony.

The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.

Investment focus

Software, SaaS, Artificial Intelligence
Seed, Funding Round, Grant
Germany, United States

Portfolio highlights

3D Spark — Profitability and Sustainability Aligned using 3D Spark's Platform - Empowering Manufacturing with Insights and Efficiency!
Stargazr — Stargazr is a AI-powered software that enables you to understand your financial data
Neuralfinity — Neuralfinity provides computer AI services. They generalise machine learning models by utilising an ML API as a service.

eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.

Investment focus

Information Technology, Software, Manufacturing
Series A, Funding Round, Series B
Germany, United States, Italy

Portfolio highlights

BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
Dryad Networks — Overview of Dryad, providing ultra-early fire detection as well as forest growth and health monitoring.
QuoIntelligence — Our finished intelligence will significantly reduce your operational risks and allow you to make informed security decisions.

Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.

Investment focus

Software, SaaS, FinTech
Series A, Seed, Series B
Germany, Switzerland, United States

Portfolio highlights

Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.

Investment focus

Software, Information Technology, Health Care
Funding Round, Series A, Series B
Germany, Italy, United States

Portfolio highlights

memtime — memtime shows you everything you worked on during the day. Each program is recorded so that you can quickly remember. Add-on available for any software. | memtime
StoryBox — StoryBox provides a Software as a Service solution for businesses to create, share and structure video content to make it searchable. With the system, companies can create and organize smartphone-based videos for any application scenario. Using the app, videos can be created and shared by every employee using templates. The app suggests picturesettings and scene lengths automatically and offers an automated creation which includes corporate design. The content can be stored in the DSGVO-compliant StoryBox cloud and can be accessed, filtered and analyzed from anywhere. Customers include Iveco, Erste Group, Evonik, Alten, and KTM.
Kloster Kitchen — Kloster Kitchen is a monastery kitchen as the root of unique taste.

bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.

Investment focus

Information Technology, Software, Manufacturing
Seed, Funding Round, Series A
Germany, United States, Austria

Portfolio highlights

Neotiv — Enabling cognitive health
RAYDIAX — We are Raydiax.Interventional only.Our goal is to reinvent computer tomography that is focussed on treatment.
InLine-Med — Radiologists perform safe, precise & easy interventions with the InLine-Med surgical tools and assistance devices.

bm|t supports innovative and growth-oriented companies in Thuringia with equity investments and venture capital.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
Germany, United States

Portfolio highlights

rooom.com — rooom is a global startup based in Germany, launched in 2019. The company’s experienceCloud is an all-in-one platform for creating, managing and promoting engaging 2D, 3D, AR & VR experiences. It works across all desktop and mobile devices. rooom’s experienceCloud is designed to cover the marketing and visualization needs of differentindustries through their comprehensive product portfolio. These include eventCloud (optimized for virtual events, exhibitions, conferences, meetings), spaceCloud (real estate, property, museums), productCloud (3D products, product showrooms) and immerseCloud (tours, guides, 3D books). rooom’s eventCloud is routinely hosting up to 200,000 users for hybrid events like IFA, Berlin and for global customers such as Porsche, Deutsche Telekom, DHL and E.ON. rooom has won over 20 awards, including the Global Eventex Award (twice), the Innovation & Excellence Award and the German Innovation Award.
tediro — tediro develops a mobile robotics platform for multiple applications in healthcare primarily therapy and diagnostics
Coachwhisperer — Coachwhisperer: The live communication system for sports. We take training to the next level and help coaches and athletes reach their true potential.

EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
Germany, Austria, Ireland

Portfolio highlights

Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.

Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, Germany, United Kingdom

Portfolio highlights

Streaming21 — Checkout the full domain details of Streaming21.com. Click Buy Now to instantly start the transaction or Make an offer to the seller!
Revolt Technology — News & Informations
Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.

Investment focus

Software, Health Care, Biotechnology
Series A, Funding Round, Series B
Germany, Switzerland, United States

Portfolio highlights

Ledgy — Digitize your cap table, automate equity plans and simplify compliance. Find out how leading companies use Ledgy to empower their employees and engage investors.
HeyJobs — Intelligent recruiting | more hires with performance marketing | only qualified candidates | fast recruiting success | over 1,500 companies use HeyJobs to find employees
Humanoo — HUMANOO | MAKING PEOPLE HEALTHIER! HUMANOO is the digital health platform for employees and insurance clients. We enable our users to improve their physical and mental health. Simple, effective, proven - all in one app. With customized programs and innovative eHealth solutions, we guide our users in the areas of fitness, physio, yoga, mindfulnessand nutrition to their self-imposed goals. For the first time, companies and insurance companies can use comprehensive decentralized analysis to understand the health of their employees or insurance clients and make it a measurable success. Our team currently consists of 65 employees from 15 nations with different talents. In our office in Berlin-Kreuzberg, software developers, designers, marketing and sales specialists work together with sports and nutrition scientists as well as yoga teachers and physiotherapists. What we share is the goal to motivate people to stay healthy.

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Investment focus

Software, Cryptocurrency, Internet
Seed, Series A, Funding Round
United States, Germany, France

Portfolio highlights

Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
ExpressionEdits — Redefining the status quo of protein expression
Transcripta Bio — Transcripta Bio is a company dedicated to drug discovery, with a focus on numerous diseases at once, at a never-before-seen pace and scale, with lesser risk and greater assurance.

start-ups, SMEs, technology, co-investment

Investment focus

Biotechnology, Health Care, Information Technology
Pre-Seed, Seed, Funding Round
Germany, The Netherlands, Austria

Portfolio highlights

Filuta AI — Operationalized Composite Artificial Intelligence
Resistell AG — Resistell is a antibiotic resistance test.
iThera Medical — Explore optoacoustic imaging technology for non-invasive in vivo visualization and quantification of disease-related tissue biomarkers.

Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Seed, Series A
Germany

Portfolio highlights

miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
Hemovent — Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.

IBB Ventures is a venture capital and mezzanine arm of Investitionsbank Berlin specializing in seed/startup, early venture, and mid venture investments. The firm invests in technology-oriented companies and companies from the creative industries. It typically invests in information and communication sector with a focus on hardware andsoftware, network technology, new media, and internet and mobile technologies; life science sector with a focus on biotechnology and media technology; and industrial technologies sector with a focus on software, PPS, supply chain management, micro and nanotechnology, environmental and power technology, automation, manufacturing technology, transport technology and logistics, and new materials. The firm also invests in movies, broadcast, television, publisher, music, entertainment, advertising, fashion, design, architecture, multimedia, games, software, and art and culture. It invests in companies based in Berlin. It typically invests between €0.25 million ($0.32 million) and €3 million ($3.83 million) per transaction. The firm prefers to take a board seat in its portfolio companies. IBB Ventures was founded in 1997 and is based in Berlin, Germany.

Investment focus

Software, Health Care, Internet
Seed, Funding Round, Series A
Germany, United States, United Kingdom

Portfolio highlights

Quantistry — Move beyond traditional chemical simulation software and boost your R&D success. From Quantum to AI. Get started!
Meloon — Meloon captures and converts carbon dioxide from the atmosphere.
Elucid Social — Elucid Social integrates businesses with the social good movement through a data-driven strategy that yields measurable results. Elucid Social develops and deploys technologies to assess, report, and minimize human rights risks linked with the sourcing of products and services.

TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Funding Round, Series C
United States, Germany, United Kingdom

Portfolio highlights

Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.

Investment focus

Biotechnology, Guides, Genetics
Series B, Funding Round, Series A
Germany

Portfolio highlights

Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields â€“ from early research to manufacturing.

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Pre-Seed
United States, Germany, United Kingdom

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
ExpressionEdits — Redefining the status quo of protein expression
Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Binx Health — Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer
Onward — Working to restore movement, independence, and health in people with spinal cord injury.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totaling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but on bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totaling €660 million. EQT Ventures III launched in 2022, with commitments totaling €1.1 billion, making it the biggest European Venture Capital fund committed to early-stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris, and San Francisco, taking a locals-with-locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has a data-driven approach and has driven more than $100 million in portfolio company investments.

Investment focus

Software, Information Technology, Artificial Intelligence
Series A, Series B, Seed
Sweden, Germany, United States

Portfolio highlights

Parloa — Transform your customer service across all channels with our customized, enterprise-ready contact center AI platform.
Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
Natural Cycles — Natural Cycles birth control is 93% effective with typical use and 98% effective with perfect use. Learn more about hormone-free birth control today.

With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).

Investment focus

Software, Information Technology, Health Care
Seed, Series A, Funding Round
Germany, United Kingdom

Portfolio highlights

Dryad Networks — Overview of Dryad, providing ultra-early fire detection as well as forest growth and health monitoring.
Mateo — Mateo is the omni-channel customer experience powerhouse that empowers local brands and businesses to drive growth through a digital customer lifecycle management. From acquiring new leads, converting them into customers and extending those relationships - all in one platform.
Captain T Cell — Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients. The company identifies novel high-efficiency TCRs for the development of T cell immunotherapies. It focuses on CMC- and preclinical development for their lead candidates.

SFO is an entrepreneur from the start-up environment and medium-sized companies. SFO offers complementary expertise, reliable capital, and an effective network.

Investment focus

Food and Beverage, B2C, Pet
Seed, Pre-Seed, Series A
Germany

Portfolio highlights

Younikat — VEGDOG - vegan dog food is the first 100% vegetable and gluten-free complete feed for dogs, which was developed in a one-year development phase in cooperation with specialist veterinarians and specialist laboratories due to a feed allergy in our dog Nelson.
ecoLocked — ecoLocked is your partner to create a climate-positive built environment. We develop CO2-optimized recipes for concrete based on carbon-negative biochar admixes. Our admixes allow to store captured CO2 in buildings, reduce direct emissions from concrete production, and provide multiple functional benefits, such as improved thermal insulation.
ProteinDistillery — ProteinDistillery: The Future of Sustainable Protein Production. We transform industrial side-streams into functional protein ingredients.

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Investment focus

Biotechnology, Health Care, Medical
Series C, Series B, Series A
United States, The Netherlands, Germany

Portfolio highlights

Karius — Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Argá Medtech — Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation Venture-capital backed company

Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.

Investment focus

Medical, Therapeutics, Biotechnology
Series A, Series B, Funding Round
Germany

Portfolio highlights

Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Series A, Series B
Germany, United States, Switzerland

Portfolio highlights

Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
anvajo — Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof.
Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.

b.value AG are into Biotechnology investments.

Investment focus

Biotechnology, Military, Textiles
Seed, Pre-Seed, Funding Round
Germany

Portfolio highlights

Revoltech — Developer of textile technology intended to transform the way material is made. Revoltech‘s first product is LOVR: the world's first plastic-free and 100% plant-based leather alternative made of agricultural residues.
FibreCoat — Making the future affordable. EM-Shielding Composites Sustainable https://fibrecoat.de/wp-content/uploads/2022/01/20211004_FibreCoat_web.mp4 Shedule a meeting to solve your problem Mobility Affordable and damage-resistant materials for integrated EMI-shielding and weight reduction in EVs. Construction Easy retrofit shielding of electronics and people from 5G and other types of EM radiation. Government Specialized yarns for sensors, circuits, shielding and countermeasure materials. With
Cultimate Foods — Cultimate Foods is a cellular agriculture company. It develops cultivated fat for hybrid alt-meat products. It's cultivated fat replicates the structure of animal fat tissue and it uses a "unique technological approach to 3D cultivation that creates the structure of their ingredient and reduces production costs."

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Series B, Funding Round
France, United States, Germany

Portfolio highlights

ID5 — ID5 provides a comprehensive suite of identification services designed to improve to improve addressability and measurement across all environments
Peptobiotics — We make agriculture more productive, humane and sustainable by promoting growth and protecting against pathogens using a new new type of antibiotic alternative that does not cause resistance. Our recombinant peptides are synthetic biology products manufactured in a patent pending precision fermentation process. We are launching a range of products across livestock and aquaculture in Asia.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Carbon removal innovation through research, development and early stage investment

Investment focus

Natural Resources, Environmental Engineering, Building Material
Seed, Series A, Pre-Seed
United Kingdom, United States, Germany

Portfolio highlights

Seqana — X-Ray-Vision” Monitoring SaaS, for Soil Organic Carbon. To fight climate change, we enable Project Developers and Agri-Food Corporates to measure and understand soil carbon sequestration in an ultra low cost, fast, precise, and affordable way. At planetary scale!
ecoLocked — ecoLocked is your partner to create a climate-positive built environment. We develop CO2-optimized recipes for concrete based on carbon-negative biochar admixes. Our admixes allow to store captured CO2 in buildings, reduce direct emissions from concrete production, and provide multiple functional benefits, such as improved thermal insulation.
Parallel Carbon — Affordable direct air capture technology based on wind, sunshine, and abundant minerals. Carbon removal and reduction, in Parallel.

Andrew Keys is the Co-Founder and Managing Partner of Andrew Keys. He previously worked for ConsenSys as a Head of Global Business Development. Andrew Keys attended Loyola University Maryland.

Investment focus

Software, Finance, Blockchain
Seed, Pre-Seed, Series A
United States, India, Norway

Portfolio highlights

Evertas — Evertas is a cryptoasset insurance company. Evertas focuses on covering institutional holders of cryptoassets including exchanges, custodians, traditional financial institutions, funds, family offices, and ultra-high net worth individuals.
Stackr Labs — Micro-rollups to scale web3 applications
Ithaca Finance — Ithaca Finance a cross-chain derivatives trading and settlements protocol, is composed of an on-chain settlement layer with an innovative off-chain matching engine.

UVC Partners is a Munich- and Berlin-based early-stage venture capital firm that invests in technology-based startups in the areas of enterprise software, industrial technologies, and mobility. The fund typically invests between € 0.5 - 10m initially and up to € 20m in total per company.

Investment focus

Software, Information Technology, SaaS
Seed, Series A, Series B
Germany, Switzerland, Denmark

Portfolio highlights

planqc — planqc quantum computers store information in individual atoms – nature's best qubits. Quantum information is processed by arranging these qubits in highly scalable arrays and manipulating them with precisely controlled laser pulses. planqc unique combination of quantum technologies is the fastest way to scale to thousands of qubits, aprerequisite for industry-relevant quantum advantage.
Isar Aerospace — Isar Aerospace is a space technology company that builds rockets in an automated production. It offers launch services dedicated to deploying and resupplying satellite constellations and to ensure low-cost space access for small satellites. The company was founded in 2018 in Europe.
Molten Industries — Decarbonizing the world's chemical and heavy industries

Taavet Hinrikus is co-founder and CEO of TransferWise. Prior to starting TransferWise, Taavet was Skype’s director of strategy until 2008, starting as its first-ever employee. One of the World Economic Forum's Tech Pioneers, Taavet is an adviser to Prime Minister of Estonia on the digital agenda. He’s also a mentor and angel investor; hisinvestments include Tweetdeck, Mendeley, OMGPOP, Property Partner, Sunrise, Improbable and Mapillary.

Investment focus

FinTech, Financial Services, Software
Seed, Series A, Series B
United Kingdom, United States, Estonia

Portfolio highlights

Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
Open Cosmos — Driven by the vision of making space accessible to anyone, Open Cosmos provides simple and affordable space missions.Open Cosmos went from design to delivery of qb01, their first nanosatellite, in only four months, followed by a launch and deployment in LEO early April 2017. They are currently working with innovative payload developers towardsin-orbit demonstration and constellation deployment to enable services ranging from remote sensing to maritime domain awareness and machine-to-machine communications.
Unearthly Materials — Unearthly Materials is a transformative materials company focused on delivering practical room-temperature superconductors and powering the century of superconductivity.

Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.

Investment focus

Internet, E-Commerce, Biotechnology
Series A, Seed, Series B
Germany, United States, Switzerland

Portfolio highlights

VYTAL — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
ZAGENO — ZAGENO is a multi-vendor, online marketplace of life science products which, by simplifying the procurement process, saves more time for science.
Hypatos — Manual document processing is a major cost driver. Hypatos' deep learning tech automates complex document processing tasks. Make back office more efficient!

LSP BioVentures is a venture capital fund focused on opportunities in the life science arena. Based in Cambridge (MA) in the USA; the fundâ€™s management combines the strength of its parent company, Life Sciences Partners Venture Capital firm in Europe and a dedicated team of experts in the USA.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Germany, United Kingdom

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.

Investing early in Europe's most passionate founders.

Investment focus

Health Care, Financial Services, Software
Seed, Series A, Funding Round
Germany, Austria, United Kingdom

Portfolio highlights

LiveEO — LiveEO is the leading solution provider for AI-powered satellite-based monitoring of large infrastructure networks. Trusted worldwide.
OneTwenty — OneTwenty is an early-stage health tech start-up that develops multiple Machine Learning based solutions for people with diabetes as well as Medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC (interoperable automated glycemic controller). Our solution demonstrates unprecedented precision in bloodglucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes.
HealthCaters — HealthCaters is a connected care solution for companies that allows them to empower their employees to take control of their health.

Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Series B, Series C
Germany, Switzerland, Slovenia

Portfolio highlights

ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research

96 Normal 0 false false false EN-GB X-NONE X-NONE

Investment focus

Medical, Health Care, Biotechnology
Series A, Seed, Series B
Germany, Finland, The Netherlands

Portfolio highlights

Surgify — Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa).
ATRO Medical — ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype.
microDimensions — microDimensions provides digital pathology software and services: image analysis, 3D histology reconstruction, protein multiplexing, stereology, image registration.

Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.

Investment focus

Software, Information Technology, Biotechnology
Seed, Pre-Seed, Series A
Germany, Australia, United States

Portfolio highlights

Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
Sumday — Non - financial accounting software. Start carbon accounting, properly, with the support of your existing advisors
InSpacePropulsion Technologies — ISPTech is a Spin-Off of the Institute of Space Propulsion at the German Aerospace Center (DLR). It offers non-toxic, green propulsion solutions

Delivery Hero Ventures is backed by Delivery Hero, a truly global food delivery platform - whose network, distribution and expertise can be harnessed to help our portfolio companies fulfill their global ambitions.

Investment focus

E-Commerce, Information Technology, Food Delivery
Series A, Seed, Series B
Singapore, Egypt, Brazil

Portfolio highlights

Charan — Charan is an operator of an e-commerce platform intended to sell second-hand fashion apparel.
Qashier — One Qashier solution streamlines POS & payment operations empowering businesses to thrive in the digital economy. Be More with Qashier.
OneOrder — One Order delivers exceptional produce, custom cuts of meat, high-quality seafood, and imported foods offering an array of global flavors.

Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.

Investment focus

Food and Beverage, Food Processing, Biotechnology
Series A, Seed, Series B
United States, Israel, United Kingdom

Portfolio highlights

ENOUGH — ENOUGH makes protein sustainable by producing ABUNDA mycoprotein, made by fermenting fungi with the natural sugars from grains. It is a whole protein with all 9 essential amino acids & rich in fibre. It is a B2B ingredient, neutral in taste and fibrous in texture, like meat. The most sustainable
PoLoPo — PoLoPo is a biotech company that produces proteins on a large scale and according to specifications. PoLoPo develops a "superAA" plant by employing directed metabolic engineering techniques and fully utilizing plants' capacity as various metabolite and green protein factories. A significant amount of free amino acids can be producedby the superAA. The increased production of amino acids is then translated into an increase in the scale at which proteins are produced in plant organs.
Wanda Fish Technologies — Wanda Fish is an innovative FoodTech company with a platform that produces a wide variety of delicious fish fillets using sustainable cell-cultivation practices.

German Federal Ministry of Education and Research (BMBF)

Investment focus

Biotechnology, Medical, Health Care
Grant, Seed, Series B
Germany, United States, Denmark

Portfolio highlights

eClear — eClear is a Pan-European payment facilitator providing Customs & VAT Clearing as embedded checkout-solution for marketplaces & platforms.
Evotec — Evotec is a global biotechnology company committed to advancing drug discovery & development together with our partners for medicines that matter.
NVision Imaging Technologies — NVision Imaging Technologies is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.

Collaboration with outstanding initiators with exceptional insights, from inception through all levels of progress. Lima Ventures supports visionary founders as well as provides certain services to early startups. We seek innovative technology-driven entrepreneurs who generate and lead companies that will inspire millions.

Investment focus

Artificial Intelligence, Software, Digital Marketing
Seed, Pre-Seed, Funding Round
Turkey, United Kingdom, Estonia

Portfolio highlights

VRLab Academy — VRLab Academy | Virtual Experiments
Studio Billion — Studio Billion is a game development company that develops applications, games, and projects for different platforms. Studio Billion is headquartered in Istanbul, Turkey.
Enqura Information Technologies — Enqura Information Technologies offers advanced technologies in conjunction with human resources as reasonable solutions. Enqura develops creative solutions in the field of digital transformation. They provide innovative and end-to-end solutions to several industries, primarily finance and insurance.

Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.

Investment focus

Biotechnology, Health Care, Medical
Series B, Private Equity, Funding Round
France, United States, Germany

Portfolio highlights

MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.

Investors by industry

FinTech

Consumer

Gaming

Media (entertainment)

EdTech

Artificial intelligence